Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in uncertain DES candidates study.

[1]  M. Jeong,et al.  Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. , 2010, Journal of the American College of Cardiology.

[2]  P. Serruys,et al.  Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial , 2012, The Lancet.

[3]  EuroPCR.  EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. , 2005 .

[4]  M. Leon,et al.  Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents. , 2010, JACC. Cardiovascular interventions.

[5]  Y. Jang,et al.  A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). , 2012, Journal of the American College of Cardiology.

[6]  M. Leon,et al.  Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. , 2011, JACC. Cardiovascular interventions.

[7]  F. Prati,et al.  Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY). , 2013, International journal of cardiology.

[8]  Y. Jang,et al.  Mini-Focus Issue: Second-Generation DESEvaluation in 3 Months Duration of Neointimal Coverage After Zotarolimus-Eluting Stent Implantation by Optical Coherence Tomography: The ENDEAVOR OCT Trial , 2009 .

[9]  A. Kirtane,et al.  The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. , 2013, JACC. Cardiovascular interventions.

[10]  F. Prati,et al.  Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. , 2008, JAMA.

[11]  Peter Jüni,et al.  Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial. , 2011, JACC. Cardiovascular interventions.

[12]  Byung Ok Kim,et al.  Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[13]  A. Kastrati,et al.  2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. , 2010, Journal of the American College of Cardiology.

[14]  R. Kuntz,et al.  Zotarolimus (ABT-578) eluting stents. , 2006, Advanced drug delivery reviews.

[15]  P. Fitzgerald,et al.  Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary , 2011, JACC. Cardiovascular interventions.

[16]  Ron Goeree,et al.  Effectiveness and safety of drug-eluting stents in Ontario. , 2007, The New England journal of medicine.

[17]  J. Marchesini,et al.  Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial , 2012, Circulation.

[18]  Marco Valgimigli,et al.  Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[19]  H. Bøtker,et al.  3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents. , 2012, JACC. Cardiovascular interventions.

[20]  R. Ferrari,et al.  Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). , 2013, European heart journal.

[21]  M. Jeong,et al.  Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. , 2009, The American journal of cardiology.

[22]  K. Kuck,et al.  Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.